Shield Therapeutics plc (STX)
LSE
5.50
+0.05 (+0.92%)
Closed
Oct 29, 2026
Day's Range
5.305.60
52 wk Range
3.7012.50
Financial Statements - STX - Shield Therapeutics plc
Revenue
49.70M▲ 54.4%
Net Income
-17.65M▲ 35.0%Net Margin -35.5%
EBITDA
-8.78M▲ 58.7%
Free Cash Flow
-3.68M▲ 60.0%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 49.70M | 32.18M | 13.08M | 5.49M | 2.05M | 14.15M |
| Cost of Goods | 26.66M | 17.25M | 9.05M | 3.04M | 1.32M | 1.84M |
| Gross Profit | 23.03M | 14.93M | 4.02M | 2.45M | 727.45K | 12.31M |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | -10.05M | -22.87M | -31.33M | -31.64M | -27.38M | -2.93M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | - | - | - | - | - | - |
| Pre Tax Income | -17.14M | -26.55M | -32.37M | -49.34M | -26.86M | -2.57M |
| Income Tax | 514K | 626K | 918K | 446K | -309.06K | 1.01M |
| Net Income | -17.65M | -27.18M | -33.29M | -49.78M | -26.55M | -3.58M |
| EPS Basic | -0.02 | -0.03 | -0.05 | -0.205734 | -0.117997 | -0.026478 |
| EPS Diluted | -0.02 | -0.03 | -0.05 | -0.205734 | -0.117997 | -0.026478 |
| Basic Shares Outstanding | 882.75M | 906.06M | 665.86M | 237.90M | 221.16M | 120.68M |
| Diluted Shares Outstanding | 882.75M | 906.06M | 665.86M | 237.90M | 221.16M | 120.68M |
| Ebit | -9.72M | -22.68M | -31.35M | -48.94M | -26.86M | -2.57M |
| Ebitda | -8.78M | -21.25M | -30.28M | -27.96M | -23.88M | 1.11M |
| Net Income Continuous Operations | -17.65M | -27.18M | -33.29M | -49.78M | -26.55M | -3.58M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | 0 | 0 | 0 | 0 | 0 | 0 |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
